SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alembic Pharma trades with traction on the BSE

11 Dec 2017 Evaluate

Alembic Pharmaceuticals is currently trading at Rs. 520.00, up by 5.30 points or 1.03% from its previous closing of Rs. 514.70 on the BSE.

The scrip opened at Rs. 521.60 and has touched a high and low of Rs. 534.90 and Rs. 518.25 respectively. So far 3246 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 709.30 on 23-Mar-2017 and a 52 week low of Rs. 469.75 on 20-Sep-2017.

Last one week high and low of the scrip stood at Rs. 534.90 and Rs. 510.00 respectively. The current market cap of the company is Rs. 9848.07 crore.

The promoters holding in the company stood at 72.68%, while institutions and non-institutions held 14.14% and 13.18% respectively.

Alembic Pharmaceuticals’ associate company -- Rhizen Pharmaceuticals SA -- has received Fast Track Designation for RP6530 (tenalisib) from United States Food & Drug Administration (USFDA). RP6530 (tenalisib) is a highly selective and orally active dual PI3K delta/gamma inhibitor, for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL).

Fast Track Designation is awarded to drugs that treat a serious condition and fill an unmet medical need.  Fast Track Designation enables the recipient to have more frequent interaction with and support from FDA, both through meetings and written communications, and also makes the drug eligible for Accelerated Approval and Priority Review.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907. The company manufactures and markets generic pharmaceuticals products all over the world.

Alembic Pharma Share Price

763.55 4.55 (0.60%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×